DAVID NEIL WATKINS

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
    D Neil Watkins
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Nature 422:313-7. 2003
  2. ncbi request reprint Hedgehog signaling: progenitor phenotype in small-cell lung cancer
    D Neil Watkins
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 572, Baltimore, MD 21231, USA
    Cell Cycle 2:196-8. 2003
  3. ncbi request reprint Hedgehog signalling in foregut malignancy
    D N Watkins
    School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Biochem Pharmacol 68:1055-60. 2004

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
    D Neil Watkins
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Nature 422:313-7. 2003
    ..This requirement for Hh pathway activation identifies a common lethal malignancy that may respond to pharmacological blockade of the Hh signalling pathway...
  2. ncbi request reprint Hedgehog signaling: progenitor phenotype in small-cell lung cancer
    D Neil Watkins
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 572, Baltimore, MD 21231, USA
    Cell Cycle 2:196-8. 2003
    ..How Hh signaling works to promote the malignant phenotype promises to be as important biologically as the promise of Hh pathway inhibitors are clinically...
  3. ncbi request reprint Hedgehog signalling in foregut malignancy
    D N Watkins
    School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Biochem Pharmacol 68:1055-60. 2004
    ..This demonstrates an ongoing requirement for Hh signalling in these highly lethal and aggressive tumors. A novel therapeutic strategy is proposed using pharmacologic targeting of Hh dependent tumors with high potency pathway antagonists...